6.25 +0.00 (0.00%)
BCRX
Stock Details
Last Trade:6.25 Change:+0.00 (0.00%) Prev Close:6.25 Open: 6.64 Days Range:6.21 – 6.71 52 Week Range: 1.15 - 13.47 Volume:1006382 P/E: N/AEPS:-0.54
View AllRecent Alerts 02/10/10
Recent Alert on 02/04/10 at 6:51am
BioCryst Pharma (BCRX) Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
BioCryst Pharma (BCRX) Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
BioCryst Pharmaceuticals (NASDAQ: BCRX) reports Q4 EPS of $0.35, which may not compare to the analyst estimate of $0.09. Revenue for the quarter was $54.9 million, which compares to the estimate of $23.66 million.
Recent Alert on 02/04/10 at 6:51am
BioCryst Pharma (BCRX) Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
BioCryst Pharma (BCRX) Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
Recent Alert on 02/03/10 at 3:58pm
Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
Trading Radar for 02/04: Bunge (BG), Spectra Energy (SE), MasterCard (MA), Con-Way (CNW), Hospira (HSP) Report
Recent Alert on 01/29/10 at 10:24am
Notable Analyst Rating Changes 1/29: WMT, BCR, MAN, URBN, ARBA Upgraded; FII, BHLB, KSP Downgraded
Notable Analyst Rating Changes 1/29: WMT, BCR, MAN, URBN, ARBA Upgraded; FII, BHLB, KSP Downgraded
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
SEC Filing on 02/09/10 at 4:07pm
Form 4 BIOCRYST PHARMACEUTICALS For: Feb 08 Filed by: SANDERS CHARLES A
Form 4 BIOCRYST PHARMACEUTICALS For: Feb 08 Filed by: SANDERS CHARLES A
View AllRecent Blog Posts
Blog Posts on 12/21/09 at 11:50am
Analyst Upgrades, Downgrades and Initiations: AA, D, H, INTC, NOK, PALM, POT, STX, V ...
Analyst Upgrades, Downgrades and Initiations: AA, D, H, INTC, NOK, PALM, POT, STX, V ...
Blog Posts on 12/09/09 at 5:18pm
BioCryst: H1N1 Antiviral Partner Gets Fast Tracked for Japanese Review
BioCryst: H1N1 Antiviral Partner Gets Fast Tracked for Japanese Review
Blog Posts on 12/03/09 at 6:12am
Cramer's Lightning Round - The Fab Four of Accelerating Revenue Growth (12/2/09)
Cramer's Lightning Round - The Fab Four of Accelerating Revenue Growth (12/2/09)